» Articles » PMID: 37792132

Updates in Small Interfering RNA for the Treatment of Dyslipidemias

Overview
Publisher Springer
Date 2023 Oct 4
PMID 37792132
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: Atherosclerotic cardiovascular disease (ASCVD) is still the leading cause of death worldwide. Despite excellent pharmacological approaches, clinical registries consistently show that many people with dyslipidemia do not achieve optimal management, and many of them are treated with low-intensity lipid-lowering therapies. Beyond the well-known association between low-density lipoprotein cholesterol (LDL-C) and cardiovascular prevention, the atherogenicity of lipoprotein(a) and the impact of triglyceride (TG)-rich lipoproteins cannot be overlooked. Within this landscape, the use of RNA-based therapies can help the treatment of difficult to target lipid disorders.

Recent Findings: The safety and efficacy of LDL-C lowering with the siRNA inclisiran has been documented in the open-label ORION-3 trial, with a follow-up of 4 years. While the outcome trial is pending, a pooled analysis of ORION-9, ORION-10, and ORION-11 has shown the potential of inclisiran to reduce composite major adverse cardiovascular events. Concerning lipoprotein(a), data of OCEAN(a)-DOSE trial with olpasiran show a dose-dependent drop in lipoprotein(a) levels with an optimal pharmacodynamic profile when administered every 12 weeks. Concerning TG lowering, although ARO-APOC3 and ARO-ANG3 are effective to lower apolipoprotein(apo)C-III and angiopoietin-like 3 (ANGPTL3) levels, these drugs are still in their infancy. In the era moving toward a personalized risk management, the use of siRNA represents a blossoming armamentarium to tackle dyslipidaemias for ASCVD risk reduction.

Citing Articles

"Inclisiran: Early LDL-C target achievement in a real-life population".

Briani F, Bagli M, Venturi G, Bacchion F, Mugnolo A Atheroscler Plus. 2025; 59:54-58.

PMID: 39996142 PMC: 11848444. DOI: 10.1016/j.athplu.2025.01.001.


Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy.

Nicholls S, Nelson A Curr Atheroscler Rep. 2025; 27(1):32.

PMID: 39954169 PMC: 11829850. DOI: 10.1007/s11883-025-01280-4.


Management of Hypercholesterolemia in Patients with Coronary Artery Disease: A Glimpse into the Future.

Sciahbasi A, Russo P, Zuccanti M, Chiorazzo L, Castelli F, Granatelli A J Clin Med. 2024; 13(23).

PMID: 39685877 PMC: 11642370. DOI: 10.3390/jcm13237420.


Lipoprotein(a) and the atherosclerotic burden - Should we wait for clinical trial evidence before taking action?.

Fichtner I, Macchi C, Rizzuto A, Carugo S, Corsini A, Ruscica M Atheroscler Plus. 2024; 58:16-23.

PMID: 39435317 PMC: 11492331. DOI: 10.1016/j.athplu.2024.09.004.


Lipid-lowering approaches to manage statin-intolerant patients.

Ruscica M, Bertoletti A, Gobbi C, Sirtori C, Carugo S, Corsini A Eur Heart J Suppl. 2024; 26(Suppl 1):i56-i59.

PMID: 38867860 PMC: 11167966. DOI: 10.1093/eurheartjsupp/suae007.


References
1.
Ray K, Raal F, Kallend D, Jaros M, Koenig W, Leiter L . Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2022; 44(2):129-138. PMC: 9825807. DOI: 10.1093/eurheartj/ehac594. View

2.
Tokgozoglu L, Libby P . The dawn of a new era of targeted lipid-lowering therapies. Eur Heart J. 2022; 43(34):3198-3208. PMC: 9448630. DOI: 10.1093/eurheartj/ehab841. View

3.
Ray K, Wright R, Kallend D, Koenig W, Leiter L, Raal F . Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020; 382(16):1507-1519. DOI: 10.1056/NEJMoa1912387. View

4.
Hu B, Huang Y . siRNA targeting ANGPTL3 stands in the spotlight for lipid-lowering therapy. Mol Ther Nucleic Acids. 2023; 32:369-370. PMC: 10148020. DOI: 10.1016/j.omtn.2023.03.020. View

5.
Carugo S, Sirtori C, Corsini A, Tokgozoglu L, Ruscica M . PCSK9 Inhibition and Risk of Diabetes: Should We Worry?. Curr Atheroscler Rep. 2022; 24(12):995-1004. PMC: 9750910. DOI: 10.1007/s11883-022-01074-y. View